Sangamo Therapeutics

History

Year	Detail
1995	Lanphier founded Sangamo in 1995 in Richmond, California. It was initially known as Sangamo Biosciences, Inc.
2015	Sangamo and Shire collaborated to explore the development of ZFP Therapeutics for hemophilia A and B and Huntington's disease.
2017	The company changed its name from Sangamo BioSciences, Inc. to Sangamo Therapeutics, Inc. The new corporate name underscores Sangamo's focus on the clinical development of genomic therapies.
2017	The company collaborated with Pfizer Inc. to develop and commercialize gene therapy programs for Hemophilia A, including SB-525.
2018	Pfizer Inc. collaborated with the company to develop gene therapy using zinc finger protein transcription factors (ZFP-TFs) to treat amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) linked to mutations of the C9ORF72 gene.
2018	Kite, a Gilead Company, collaborated with Sangamo Therapeutics Inc. to develop next-generation engineered cell therapies for cancer treatment.
2018	The company acquired TxCell, SA., to develop a pipeline of novel cell therapies for patients with autoimmune and inflammatory disorders.
2019	The company completed the transfer of the SB-525 Hemophilia A gene therapy Investigational New Drug application to Pfizer and earned a $25 million milestone payment.
2020	Biogen and Sangamo collaborated to develop gene regulation therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases. Biogen pays Sangamo $350 million upfront, including a license fee and an equity investment in Sangamo stock.
2020	Sangamo collaborated with Novartis to develop genomic medicines for autism and other neurodevelopmental disorders. The company receives a $75M upfront licensing fee and royalties on potential net commercial sales.
2023	The company collaborated with Voyager Therapeutics, Inc., on a potential treatment for prion disease. The company developed zinc finger transcriptional regulators (ZF-TRs), which can specifically and potently block the expression of the prion protein, the pathogenic driver of prion disease.
2023	The company signed an evaluation and option agreement with Prevail Therapeutics, a wholly-owned subsidiary of Eli Lilly and Company. Through this agreement, Prevail has been granted rights to evaluate specific proprietary adeno-associated virus (AAV) capsids developed by Sangamo and may exercise specific options to license these capsids for multiple undisclosed neurological targets.
2023	The company entered into a research evaluation, option, and license agreement with Chroma Medicine, Inc., a genomic medicine company, to develop epigenetic medicines that leverage zinc finger proteins (ZFPs) for sequence-specific DNA recognition.